Last checked 30 September 2026. General information, not legal or regulatory advice. bioaccess® is not affiliated with Laura Minarsch, MMC Medical, or MMC Medical International Consulting Services. Their names are used here only to identify them. Statements about Laura Minarsch and MMC Medical are taken from the public case study and podcast listed below (sources) and are presented as the publisher's claims. Offers and facts change, so confirm current terms with each provider.
Laura Minarsch is the founder and President of MMC Medical International Consulting Services, a specialized first-in-human medical-device CRO reportedly founded in 1992. A published case study reports 70+ device studies completed since 2019 and 15–18 studies managed concurrently; its much-cited "five hours" figure refers to electronic data capture (EDC) study builds, not whole clinical trials. Julio G. Martinez-Clark, bioaccess® co-founder and CEO, interviewed Laura on the Global Trial Accelerators podcast in October 2019 (Season 2, Episode 4) and for Med Device Online the same year.
Laura Minarsch is the founder and President of MMC Medical International Consulting Services, a boutique clinical research organization headquartered in Laguna Beach, California (per its public company profile). The company describes itself as a specialized first-in-human medical-device CRO focused on rapid execution, with roots in interventional cardiology. It self-describes its model as strategic clinical affairs consulting for the medical device industry, without bureaucratic or financial barriers.
A G2-published Castor EDC case study about the company reports that it has completed 70+ device studies since 2019 and manages 15–18 studies concurrently. The headline "five hours" figure from that case study refers to the time needed to build a study's electronic data capture setup — not the time to run a clinical trial. For a representative device study, the case study reports four to six weeks from protocol to first patient.
On the Global Trial Accelerators podcast (Season 2, Episode 4, October 26, 2019), Laura described operations across four continents, with early operations outside the United States running through Paraguay, Lithuania, and New Zealand. The company's published strength is early-stage and first-in-human device studies, particularly in interventional cardiology and vascular access.
bioaccess® and Laura Minarsch go back. Julio G. Martinez-Clark, bioaccess® co-founder and CEO, interviewed Laura for Med Device Online in 2019 for an article on the EU Medical Device Regulation, and interviewed her on the Global Trial Accelerators podcast (Season 2, Episode 4, October 26, 2019) to discuss first-in-human trial strategy for medical devices. Laura was re-invited to the podcast in September 2026.
We hold MMC Medical in genuine regard: it is a credible, long-tenured specialist that has spent decades doing one thing — first-in-human medical-device trials — and doing it fast. This page exists to give sponsors searching for Laura an honest picture of who she is, and an honest account of how bioaccess® compares.
If you are here because you are evaluating a first-in-human CRO, here is how bioaccess® compares to MMC Medical. MMC is a credible choice when the geography question is settled and you want a long-tenured, rapid-execution specialist. bioaccess® is the geography-neutral alternative: an honest assessment of whether your program belongs in a U.S. Early Feasibility Study or a Latin American first-in-human, FDA strategy anchored in Miami, execution across 19 Latin American countries or at our Miami cardiovascular site where the device and study fit, and a 12-month protocol-to-last-patient-last-visit written guarantee.
Read the full head-to-head: bioaccess® vs. MMC Medical. Or book a free 30-min strategy call and we will tell you honestly which path your program belongs on.
Laura Minarsch is the founder and President of MMC Medical International Consulting Services, a specialized first-in-human medical-device CRO reportedly founded in 1992 and headquartered in Laguna Beach, California. She is widely cited for the company's rapid-execution model for early-stage device studies.
MMC Medical International Consulting Services is a boutique CRO focused on first-in-human medical-device trials and strategic clinical affairs consulting. A published case study reports 70+ device studies completed since 2019 and 15–18 studies managed concurrently, with early operations outside the United States described across Paraguay, Lithuania, and New Zealand.
It refers to electronic data capture (EDC) study builds — the time to stand up a study's data-capture setup — not the duration of a clinical trial. The figure comes from a G2-published Castor EDC case study about MMC Medical and is presented here as the publisher's claim.
Yes. Julio G. Martinez-Clark, co-founder and CEO of bioaccess®, interviewed Laura Minarsch on the Global Trial Accelerators podcast (Season 2, Episode 4, October 26, 2019) and for Med Device Online in 2019 for an article on the EU Medical Device Regulation. She was re-invited to the podcast in September 2026.
All CRO comparisons · bioaccess® vs. MMC Medical · Book a free 30-min strategy call